Sibylle M. Schliemann

Erfurter Str. 35
Jena, TH 07743, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 133 publications

Update on the assessment of the impact of occupational contact allergies in case of occupational skin disease no. 5101

Update on the assessment of the impact of occupational contact allergies in case of occupational skin disease no. 5101

Journal: Dermatologie (Heidelberg, Germany)

Published: February 28, 2026

Correction to: Summary of Research: Efficacy and Safety of Delgocitinib Cream in Adults with Moderate to Severe Chronic Hand Eczema (DELTA 1 and DELTA 2): Results from Multicentre, Randomised, Controlled, Double‑Blind, Phase 3 Trials.

Correction to: Summary of Research: Efficacy and Safety of Delgocitinib Cream in Adults with Moderate to Severe Chronic Hand Eczema (DELTA 1 and DELTA 2): Results from Multicentre, Randomised, Controlled, Double‑Blind, Phase 3 Trials.

Journal: American journal of clinical dermatology

Published: November 01, 2025

The International Guideline for the Definition, Classification, Diagnosis and Management of Urticaria.

The International Guideline for the Definition, Classification, Diagnosis and Management of Urticaria.

Journal: Allergy

Published: October 15, 2025

The International Guideline for the Definition, Classification, Diagnosis and Management of Urticaria.

The International Guideline for the Definition, Classification, Diagnosis and Management of Urticaria.

Journal: Allergy

Published: October 15, 2025

The International Guideline for the Definition, Classification, Diagnosis and Management of Urticaria.

The International Guideline for the Definition, Classification, Diagnosis and Management of Urticaria.

Journal: Allergy

Published: October 15, 2025

Summary of Research: Efficacy and Safety of Delgocitinib Cream in Adults with Moderate to Severe Chronic Hand Eczema (DELTA 1 and DELTA 2): Results from Multicentre, Randomised, Controlled, Double-Blind, Phase 3 Trials.

Summary of Research: Efficacy and Safety of Delgocitinib Cream in Adults with Moderate to Severe Chronic Hand Eczema (DELTA 1 and DELTA 2): Results from Multicentre, Randomised, Controlled, Double-Blind, Phase 3 Trials.

Journal: American journal of clinical dermatology

Published: July 23, 2025

Reflections on chronic hand eczema - Authors' reply.

Reflections on chronic hand eczema - Authors' reply.

Journal: Lancet (London, England)

Published: January 24, 2025

Long-term safety and efficacy of delgocitinib cream for up to 52 weeks in adults with Chronic Hand Eczema: Results of the phase 3 open-label extension DELTA 3 trial following the DELTA 1 and 2 trials.

Long-term safety and efficacy of delgocitinib cream for up to 52 weeks in adults with Chronic Hand Eczema: Results of the phase 3 open-label extension DELTA 3 trial following the DELTA 1 and 2 trials.

Journal: Journal of the American Academy of Dermatology

Published: September 24, 2024

Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials.

Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials.

Journal: Lancet (London, England)

Published: January 29, 2024

Treatment of mucocutaneous leishmaniasis - A systematic review.

Treatment of mucocutaneous leishmaniasis - A systematic review.

Journal: Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG

Published: November 21, 2023

European patch test results with audit allergens as candidates for inclusion in the European Baseline Series, 2019/20: Joint results of the ESSCAA and the EBSB working groups of the ESCD, and the GEIDACC.

European patch test results with audit allergens as candidates for inclusion in the European Baseline Series, 2019/20: Joint results of the ESSCAA and the EBSB working groups of the ESCD, and the GEIDACC.

Journal: Contact dermatitis

Published: December 13, 2021

The pan-JAK inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16-week randomized phase IIb trial.

The pan-JAK inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16-week randomized phase IIb trial.

Journal: The British journal of dermatology

Published: October 01, 2021

Showing 1-12 of 133

Last Updated: 09/26/2026